Krystal Biotech Inc (KRYS)

Debt-to-assets ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total assets	US$ in thousands	853,296	818,355	790,350	684,026	531,847	558,450	576,379	601,324	616,874	626,295	451,095	443,556	443,018	310,844	311,451	318,145	205,131	209,023	214,232	205,156
Debt-to-assets ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

March 31, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $853,296K
= 0.00

The debt-to-assets ratio for Krystal Biotech Inc has consistently remained at 0.00 for all the reported periods. This indicates that the company has not used any debt financing to fund its operations and investments, relying solely on equity financing or retained earnings.

A debt-to-assets ratio of 0.00 suggests that the company has a conservative financial structure with low financial risk associated with debt. It implies that all assets of the company are financed either through equity or internal funds.

While a low debt-to-assets ratio is generally viewed positively as it signifies financial stability and lower interest expense, it is essential to note that too low a ratio may also indicate underutilization of debt financing, which could potentially limit the company's growth opportunities or tax efficiency.

In the case of Krystal Biotech Inc, maintaining a consistent 0.00 debt-to-assets ratio could reflect a strategic decision to prioritize financial prudence and stability in its capital structure. Further analysis of other financial metrics and the company's strategic objectives would provide a more comprehensive understanding of its financial health and growth prospects.